BA
ALNY icon

Bridgewater Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bridgewater Associates’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30M Sell
99,584
-7,008
-7% -$2.11M 0.12% 136
2026
Q1 		$35.3M Buy
106,592
+20,975
+24% +$7.14M 0.16% 95
2025
Q4 		$34M Buy
85,617
+51,706
+152% +$22.9M 0.12% 131
2025
Q3 		$15.5M Buy
+33,911
New +$13.8M 0.06% 249
2025
Q1 		– Sell
-6,452
Closed -$1.52M – 674
2024
Q4 		$1.52M Buy
6,452
+4,450
+222% +$1.17M 0.01% 467
2024
Q3 		$551K Buy
+2,002
New +$521K ﹤0.01% 681
2024
Q1 		– Sell
-1,951
Closed -$373K – 684
2023
Q4 		$373K Buy
1,951
+65
+3% +$11.1K ﹤0.01% 723
2023
Q3 		$334K Buy
1,886
+90
+5% +$17.2K ﹤0.01% 718
2023
Q2 		$341K Buy
1,796
+541
+43% +$107K ﹤0.01% 674
2023
Q1 		$251K Buy
+1,255
New +$264K ﹤0.01% 689
2022
Q4 		– Sell
-1,283
Closed -$257K – 823
2022
Q3 		$257K Sell
1,283
-229
-15% -$43.7K ﹤0.01% 835
2022
Q2 		$221K Buy
+1,512
New +$215K ﹤0.01% 967
2021
Q4 		– Sell
-2,234
Closed -$422K – 734
2021
Q3 		$422K Sell
2,234
-3,865
-63% -$725K ﹤0.01% 604
2021
Q2 		$1.03M Buy
+6,099
New +$893K 0.01% 581

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgewater Associates's ALNY Position: Q2 2026 in Review

Bridgewater Associates reduced its Alnylam Pharmaceuticals (ALNY) stake by 6.6% in Q2 2026, selling an estimated $2.11M and leaving 99,584 shares worth $30M. The position accounts for 0.12% of the portfolio, ranked #136.

Bridgewater Associates first reported a position in ALNY in Q2 2021 and has held it in 14 quarters since. The position peaked at $35.3M in Q1 2026. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Bridgewater Associates held 99,584 shares of Alnylam Pharmaceuticals worth $30M as of Q2 2026.
  • Bridgewater Associates sold 7,008 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $2.11M.
  • Alnylam Pharmaceuticals made up 0.12% of Bridgewater Associates's portfolio in Q2 2026, its #136 holding.
  • Bridgewater Associates first reported a position in Alnylam Pharmaceuticals in Q2 2021 and has held it in 14 quarters since.
  • Bridgewater Associates's Alnylam Pharmaceuticals position peaked at $35.3M in Q1 2026.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.